Role of PML nuclear body proteins for establishment of EBV latent infection

描述（由申请人提供）：eb病毒（EBV）是最有效的转化病毒之一，在几种人类癌症中发现，包括艾滋病患者免疫抑制的B细胞淋巴瘤。我们实验室的长期目标是了解eb病毒潜伏蛋白如何介导B细胞转化。特别令人感兴趣的是EBNA2和EBNA-LP转录因子。EBNA2部分通过模仿细胞Notch信号通路来诱导病毒和细胞基因的表达。EBNA-LP是EBNA2的共激活剂，但其协同激活EBNA2的机制尚不清楚。我们实验室最近的观察表明，ena - lp与PML NB中的早幼粒细胞核体（PML NB）蛋白Sp100相互作用并取代PML NB中的Sp100，表明Sp100是介导ena - lp共激活功能的重要细胞辅助因子。此外，我们已经证明EBNA2氨基酸残基1-58包含一个寡聚化结构域，该结构域能够作为EBNA2转录激活功能的显性负抑制剂。为了进一步阐明Sp100如何介导EBNA-LP共激活功能，并测试EBNA2寡聚化结构域是否可以被利用来抑制ebv驱动的B细胞永生化，我们制定了以下目标：1)确定EBNA-LP如何介导PML NBs中Sp100的移位，以及Sp100是否对EBNA2的共激活至关重要；2)确定Sp100参与EBNA-LP共激活功能的机制；3)确定EBNA2的显性阴性形式是否可以抑制ebv诱导的B淋巴细胞永生。疱疹病毒修饰和/或调节PML和PML相关的NB蛋白。然而，目前尚不清楚PML-NBs是否是介导疱疹病毒进化来抵消的抗病毒细胞防御机制的蛋白质集合，或者病毒是否会利用PML-NBs中的因子来帮助促进病毒基因表达和/或复制。我们对EBNA-LP与Sp100之间独特相互作用的研究将有助于对疱疹病毒与PML NBs的关系产生新的见解。设计EBNA2和/或EBNA-LP抑制剂是我们研究中潜在的实际应用。

DESCRIPTION (provided by applicant): Epstein-Barr virus (EBV) is one of the most potent transforming viruses and it is found in several human cancers, including B cell lymphomas in patients with AIDS who are immunosuppressed by HIV. The long- term goal of our laboratory is to understand how EBV latent proteins mediate B cell transformation. Of particular interest are the EBNA2 and EBNA-LP transcription factors. EBNA2 functions in part through mimicry of cellular Notch signaling pathways to induce expression of viral and cellular genes. EBNA-LP is a coactivator of EBNA2, but the mechanism(s) by which it coactivates EBNA2 remains elusive. Recent observations from our laboratory indicate that EBNA-LP interacts with and displaces the promyelocytic nuclear body (PML NB) protein Sp100 from PML NBs, suggesting that Sp100 is an important cellular cofactor that mediates EBNA-LP coactivation function. In addition, we have demonstrated that EBNA2 amino acid residues 1-58 comprise an oligomerization domain that is able to act as a dominant negative inhibitor of EBNA2 transcriptional activation function. To further clarify how Sp100 mediates EBNA-LP coactivation function and to test whether the EBNA2 oligomerization domain can be harnessed to inhibit EBV-driven B cell immortalization, we have developed the following aims: 1) To determine how EBNA-LP mediates Sp100 displacement from PML NBs and if Sp100 is essential for EBNA2 coactivation, 2) To determine the mechanism by which Sp100 contributes to EBNA-LP coactivation function, and 3) To determine whether dominant negative forms of EBNA2 can inhibit EBV-induced B lymphocyte immortalization. Herpesviruses modify and/or modulate PML and PML-associated NB proteins. However, it remains unclear whether PML NBs are a collection of proteins that mediate an antiviral cellular defense mechanism that herpesviruses have evolved to counteract or if viruses co-opt factors in PML-NBs to their advantage to help facilitate virus gene expression and/or replication. Our investigations into the unique interaction between EBNA-LP and Sp100 will help to yield new insights into the relationship of herpesviruses and PML NBs. Design of EBNA2 and/or EBNA-LP inhibitors is a potential practical application that will be derived from our studies.